Merus NV (Merus NV) Total Liabilities : $99.15 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Merus NV Total Liabilities?

Merus NV's Total Liabilities for the quarter that ended in Dec. 2023 was $99.15 Mil.

Merus NV's quarterly Total Liabilities declined from Jun. 2023 ($106.22 Mil) to Sep. 2023 ($98.80 Mil) but then increased from Sep. 2023 ($98.80 Mil) to Dec. 2023 ($99.15 Mil).

Merus NV's annual Total Liabilities declined from Dec. 2021 ($140.40 Mil) to Dec. 2022 ($129.49 Mil) and declined from Dec. 2022 ($129.49 Mil) to Dec. 2023 ($99.15 Mil).

Merus NV Total Liabilities Historical Data

The historical data trend for Merus NV's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merus NV Total Liabilities Chart

Merus NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

132.08

128.95

140.40

129.49

99.15

Merus NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															129.49	121.00	106.22	98.80	99.15

Merus NV Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Merus NV's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	69.089	+	(10.488	+	-3.5527136788005E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	19.574	+	0)
	=	99.15

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	455.494	-	356.343
	=	99.15

Merus NV's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	69.089	+	(10.488	+	-3.5527136788005E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	19.574	+	0)
	=	99.15

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	455.494	-	356.343
	=	99.15

Merus NV Total Liabilities Related Terms

Thank you for viewing the detailed overview of Merus NV's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Merus NV (Merus NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merus NV (NAS:MRUS) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

2GH:Germany

Address

Uppsalalaan 17, Utrecht, NLD, 3584 CT

Website

https://www.merus.nl

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

Executives

Harry Shuman	officer: Chief Accounting Officer	C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Peter B. Silverman	officer: EVP & General Counsel	C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Sven Ante Lundberg	director, officer: President, CEO & PFO	C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Kruif John De	officer: Chief Technology Officer	C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Paolo Pucci	director	C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Len Kanavy	director	C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Maxine Gowen	director
Anand Mehra	director	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Victor Sandor	director	C/O ARRAY BIOPHARMA INC., 3200 WALNUT STREET, BOULDER CO 80301
Mark T Iwicki	director	84 WATERFORD DRIVE, MARLBOROUGH MA 01752
Gregory D Perry	director	C/O IMMUNOGEN, INC., 830 WINTER ST., WALTHAM MA 02451
Geuijen Cecile A W	officer: SVP & Chief Scientific Officer	C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584CM
Andrew Joe	officer: SVP, CMO	C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Mark Throsby	officer: EVP & Chief Scientific Officer	C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM